FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to biotechnology and immunology. An antibody contains no amino acid substitutes specific for camelids and contains FR2 substitutes not found in the antibodies contains heavy and light chains. The antibody possess a high total hydrophobic nature in CDR1 and contains an extended number of charged amino acids found in CDR3, and contains one or more amino acid substitutes in β-sheet of a framework region which lead to the higher total hydrophobic nature in FR1 and to the more extended number of the charged amino acids found in FR3. There are also presented VH domains which possess the same properties, gene segments for preparing them, methods for preparing them and using the antibodies of VH domains in therapy.
EFFECT: what is disclosed in the high-affinity antigen-specific soluble antibody containing only heavy chains.
14 cl, 26 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING ANTIGEN-BINDING V DOMAIN, APPLICATION THEREOF | 2005 |
|
RU2398882C2 |
| TRANSGENIC ANIMALS, OTHER THAN HUMANS, PRODUCING MODIFIED ANTIBODIES CONTAINING ONLY HEAVY CHAINS | 2017 |
|
RU2762835C2 |
| OBTAINING ANTIBODIES FROM SAME HEAVY CHAINS IN TRANSGENIC ANIMALS | 2007 |
|
RU2435784C2 |
| MICE THAT MAKE HEAVY CHAIN ANTIBODIES | 2010 |
|
RU2603102C2 |
| BCMA HEAVY CHAIN ANTIBODIES | 2018 |
|
RU2816994C2 |
| HEAVY CHAIN-ONLY ANTIBODIES THAT BIND TO CD19 | 2019 |
|
RU2824170C2 |
| BISPECIFIC ANTI-HER2 / ANTI-HER3 ANTIBODIES | 2016 |
|
RU2653443C2 |
| HIGH AFFINITY AND AGGREGATIONALLY STABLE ANTIBODIES BASED ON VL VARIABLE DOMAINS AND VHH DERIVATIVE | 2014 |
|
RU2609627C2 |
| HUMANISED ANTI-LIGHT ANTIBODIES AND USING THEM | 2010 |
|
RU2542394C2 |
| HUMANISED UNIVERSAL LIGHT CHAIN MICE | 2012 |
|
RU2664232C2 |
